Deal Tracker · Countries

Spain pharma deals

7 pharma deals involving Spain — companies based there or deals covering the market — tracked by EPT: licensing, distribution & localization. Most active: Galenicum, Faes Farma, Al Ittihad Drug Store & CCL Pharmaceuticals. Latest: Galenicum → Al Ittihad Drug Store (Distribution, 31 Oct 2026).

7
deals tracked
6
announced in 2026
$310m
disclosed value (1 deal)
43%
licensing, the top deal type
  • EPT has tracked 7 Spain pharma deals (2025–2026), 6 of them announced in 2026.
  • The most common structures are licensing (43%), distribution (14%) & m&a (14%).
  • Values were disclosed for 1 of 7 deals, totalling $310m; the largest is Faes Farma → SIFI ($310m, 2 Sept 2025).
  • The most active companies: Galenicum (3) & Faes Farma (2).

Most active companies

Galenicum (3) · Faes Farma (2)

Countries involved

UAE (3) · Bahrain (1) · India (1) · Italy (1) · Jordan (1) · Latvia (1)

Largest disclosed deals

Questions

How many Spain pharma deals has EPT tracked?
7 as of 31 Oct 2026, covering 2025–2026; 6 were announced in 2026. The most recent is Galenicum → Al Ittihad Drug Store (Distribution, 31 Oct 2026).
What types of Spain pharma deals are most common?
Licensing: 3 (43%); Distribution: 1 (14%); M&A / Acquisition: 1 (14%); Supply / Manufacturing: 1 (14%).
Which companies are most active in Spain pharma deals?
Galenicum (3 deals), Faes Farma (2 deals).
What is the largest disclosed Spain pharma deal?
Faes Farma → SIFI: $310m (M&A / Acquisition, 2 Sept 2025). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)